Fortress Biotech, Inc. Chief Financial Officer David Jin filed a Form 4 on November 19, 2026, disclosing three open-market purchases of common stock totaling 47,605 shares between November 17 and November 19, 2026.

Key Highlights

  • Three purchases in three days: David Jin acquired 15,000 shares on November 17, 25,000 shares on November 18, and 7,605 shares on November 19, 2026.
  • Weighted average prices: The per-share weighted average prices were $1.7197, $1.9119, and $1.8699, respectively, according to the filing.
  • Price ranges disclosed: Shares were purchased in ranges of $1.71 to $1.72 on November 17, $1.8999 to $1.96 on November 18, and $1.865 to $1.87 on November 19, all inclusive.
  • Resulting beneficial ownership: Following the final transaction, Jin's direct beneficial ownership stood at 1,700,366 shares of common stock, par value $0.001.
  • Deferred and restricted units included: The total holdings figure includes 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units, according to the filing.
  • Transaction code: All three transactions were coded "P" (open-market purchase) with no derivative securities involved.

CFO David Jin's Open-Market Purchases of Fortress Biotech Common Stock

According to the Form 4 filed with the SEC on November 19, 2026, David Jin, Chief Financial Officer of Fortress Biotech, Inc. (NASDAQ:FBIO), reported three separate open-market purchases of the company's common stock over consecutive trading days. On November 17, 2026, Jin acquired 15,000 shares at a weighted average price of $1.7197. The following day, he purchased an additional 25,000 shares at a weighted average of $1.9119. On November 19, 2026, the date of filing, he acquired a further 7,605 shares at a weighted average price of $1.8699.

The filing notes that the reported prices are weighted averages, as shares were purchased in multiple transactions within the stated ranges on each day. The filing states that Jin "undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this note."

Following the three transactions, Jin's direct beneficial ownership totaled 1,700,366 shares. The filing clarifies that this total includes 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units. No derivative securities were reported as acquired or disposed of. The transactions were each coded "P," indicating open-market purchases, and no Rule 10b5-1 plan checkbox was indicated on the filing.

What Was Disclosed

Fortress Biotech CFO David Jin disclosed three open-market purchases of company common stock between November 17 and November 19, 2026, totaling 47,605 shares at weighted average prices ranging from $1.7197 to $1.9119, bringing his direct beneficial ownership to 1,700,366 shares.